These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 8021435)

  • 1. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs).
    Hyttel J
    Int Clin Psychopharmacol; 1994 Mar; 9 Suppl 1():19-26. PubMed ID: 8021435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.
    Sánchez C; Hyttel J
    Cell Mol Neurobiol; 1999 Aug; 19(4):467-89. PubMed ID: 10379421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
    Baumann P
    Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH; Goa KL
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of selective serotonin reuptake inhibitors.
    van Harten J
    Clin Pharmacokinet; 1993 Mar; 24(3):203-20. PubMed ID: 8384945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
    Preskorn SH
    Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology and pharmacokinetics of citalopram and other SSRIs.
    Baumann P
    Int Clin Psychopharmacol; 1996 Mar; 11 Suppl 1():5-11. PubMed ID: 8732438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.
    Baumann P; Rochat B
    Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 1():15-21. PubMed ID: 7622807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic optimisation of therapy with newer antidepressants.
    Goodnick PJ
    Clin Pharmacokinet; 1994 Oct; 27(4):307-30. PubMed ID: 7834966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fluoxetine: an update of its use in major depressive disorder in adults].
    Gourion D; Perrin E; Quintin P
    Encephale; 2004; 30(4):392-9. PubMed ID: 15597466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of the 5-HT2 receptor antagonist on the anti-immobility effects of noradrenaline and serotonin reuptake inhibitors in the forced swimming test.
    Yamada J; Sugimoto Y
    Brain Res; 2002 Dec; 958(1):161-5. PubMed ID: 12468041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex.
    Felton TM; Kang TB; Hjorth S; Auerbach SB
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Mar; 367(3):297-305. PubMed ID: 12644903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of the pharmacology of serotonin reuptake inhibitors.
    Warrington SJ
    Int Clin Psychopharmacol; 1992 Oct; 7 Suppl 2():13-9. PubMed ID: 1484174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacogenetics of the selective serotonin reuptake inhibitors.
    Brøsen K
    Clin Investig; 1993 Dec; 71(12):1002-9. PubMed ID: 8124052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.
    Caccia S
    Clin Pharmacokinet; 1998 Apr; 34(4):281-302. PubMed ID: 9571301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.
    Sproule BA; Naranjo CA; Brenmer KE; Hassan PC
    Clin Pharmacokinet; 1997 Dec; 33(6):454-71. PubMed ID: 9435993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective serotonin reuptake inhibitors in affective disorders--I. Basic pharmacology.
    Goodnick PJ; Goldstein BJ
    J Psychopharmacol; 1998; 12(3 Suppl B):S5-20. PubMed ID: 9808077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation-induced aggression in mice: effects of 5-hydroxytryptamine uptake inhibitors and involvement of postsynaptic 5-HT1A receptors.
    Sánchez C; Hyttel J
    Eur J Pharmacol; 1994 Nov; 264(3):241-7. PubMed ID: 7698161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoamine neurocircuitry in depression and strategies for new treatments.
    Hamon M; Blier P
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of 5-HT(2C) receptors in the anti-immobility effects of antidepressants in the forced swimming test in mice.
    Clenet F; De Vos A; Bourin M
    Eur Neuropsychopharmacol; 2001 Apr; 11(2):145-52. PubMed ID: 11313160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.